514 related articles for article (PubMed ID: 33973870)
1. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhou X; Guo S; Jiang S; Zhang Y; Zhang R; Dong J; Liao L
Aging (Albany NY); 2021 May; 13(9):12748-12765. PubMed ID: 33973870
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
5. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
7. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Zhang Q; Dou J; Lu J
Diabetes Res Clin Pract; 2014 Sep; 105(3):313-21. PubMed ID: 25015317
[TBL] [Abstract][Full Text] [Related]
8. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
9. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis.
Li M; Wang S; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):320-326. PubMed ID: 37171944
[TBL] [Abstract][Full Text] [Related]
12. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Wang H; Yao G; Chen X; Ouyang J; Yang J
Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Zhuang Y; Song J; Ying M; Li M
Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
16. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]